Pioneering Collaboration Unveils Charitable Lecture on Cutting-Edge Cancer Prevention

"Cancer: The Integrative Perspective" is #1 on Amazon Special Interests New Releases

Investment will be used to advance its novel vapor-based ablation system to treat precancerous conditions and metabolic disease such as type 2 diabetes in the gastrointestinal (GI) tract.

CMS Oncology Care Model attracts almost twice the expected number of physician group practices

Highlands Oncology Group Will Celebrate 20th Anniversary in June

NWA Oncology Group Encourages Cancer Prevention And Awareness In February

Public attention focused on early detection and strategies to prevent breast cancer.

A new blood-based genetic test might predict the presence of dangerous BRCA1 or BRCA2 gene mutations in women, according to a study published in the January 22 issue of Cancer Prevention Research.

Atossa Genetics develops noninvasive method of nipple aspirate fluid collection for cytological testing.

Atossa Genetics developing diagnostic and therapeutic system in effort to curb trend.

An estimated 25 million Americans are at risk from radon in their homes. RadonAway promotes radon risk reduction through radon testing and, if radon levels are high, radon mitigation.

Lung cancer survivors and radon experts welcomed the spotlight that was shone on radon by Fox's "Dr. Oz Show," when Dr. Mehmet Oz described radon as an "incredibly toxic" radioactive gas that is the "number one cancer risk at home."

RadonAway and AccuStar Labs participated in the AARST Radon Symposium in Columbus, OH, sponsoring CE courses, exhibiting products, and supporting initiatives for RRNC and increased public awareness. AccuStar's Carolyn Allen is AARST's new President.

The Reduce Radon Tee traveled Boston's Freedom Trail to promote radon awareness, to reduce the number of radon-induced lung cancer deaths, and to support Cancer Survivors Against Radon (CanSAR).